J III Biography and Net Worth

Ed brings more than 20 years of combined finance, business development and corporate strategy experience to Intellia. Most recently, he served as CFO of Fate Therapeutics. Prior to that role, Ed spent numerous years at Celgene (now Bristol Myers Squibb), a leading global biopharmaceutical company, where he held multiple positions including as vice president, Business Development & Strategy. Prior to Celgene, he worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers and in corporate finance at Pfizer.

He holds a Bachelor of Pharmacy from the University of Pittsburgh and an MBA from Indiana University, Kelley School of Business.

What is J Dulac III's net worth?: The estimated net worth of J Dulac III is at least $1.03 million as of July 23rd, 2025. III owns 106,062 shares of Intellia Therapeutics stock worth more than $1,033,044 as of December 5th. This net worth approximation does not reflect any other investments that III may own. Learn More about J Dulac III's net worth.
How do I contact J Dulac III?: The corporate mailing address for III and other Intellia Therapeutics executives is 40 Erie Street Suite 130, Cambridge MA, 02139. Intellia Therapeutics can also be reached via phone at (857) 285-6200 and via email at [email protected]. Learn More on J Dulac III's contact information.
Has J Dulac III been buying or selling shares of Intellia Therapeutics?: J Dulac III has not been actively trading shares of Intellia Therapeutics within the last three months. Most recently, Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $14.02, for a transaction totalling $104,617.24. Following the completion of the sale, the executive vice president now directly owns 106,062 shares of the company's stock, valued at $1,486,989.24. Learn More on J Dulac III's trading history.
Who are Intellia Therapeutics' active insiders?: Intellia Therapeutics' insider roster includes James Basta (EVP, General Counsel and Corporate Secretary), William Chase (Director), Eliana Clark (EVP), John Crowley (Director), Caroline Dorsa (Director), Michael Dube (CAO), Jean-Francois Formela (Director), Glenn Goddard (CFO), Jesse Goodman (Director), J III (EVP), David Lebwohl (EVP), John Leonard (CEO), Jose Rivera (EVP), Andrew Schiermeier (COO), Birgit Schultes (EVP), and Laura Sepp-Lorenzino (EVP). Learn More on Intellia Therapeutics' active insiders.
Are insiders buying or selling shares of Intellia Therapeutics?: In the last year, Intellia Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $1,003,000.00. In the last year, insiders at the sold shares 11 times. They sold a total of 43,701 shares worth more than $541,697.15. The most recent insider tranaction occured on October, 1st when EVP Birgit C Schultes sold 31 shares worth more than $538.78. Insiders at Intellia Therapeutics own 3.1% of the company. Learn More about insider trades at Intellia Therapeutics.
Information on this page was last updated on 10/1/2025.

J Dulac III Insider Trading History at Intellia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/23/2025	Sell	7,462	$14.02	$104,617.24	106,062

J Dulac III Buying and Selling Activity at Intellia Therapeutics

Intellia Therapeutics Company Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $9.74

$8.85

$9.92

50 Day Range

MA: $15.47

$8.04

$27.98

2 Week Range

Now: $9.74

$5.90

$28.25

Volume

5,893,115 shs

Average Volume

6,755,643 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.13